Surface expression of transforming growth factor beta 1 (TGF-β) on CD4+ CD25+ Foxp3+ Tregs controls the expression of key NK cell activation receptors – NKp30, NKG2D, and CD16 (77–80)– and neutralizes the potent anti-tumor NK cell response. The gene discussed is KLRK1; the disease is neoplasm.